Combination Therapy with Oral Tacrolimus (FK506) and Azathioprine or 6-Mercaptopurine for Treatment-Refractory Crohnʼs Disease Perianal Fistulae
- 1 November 1999
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 5 (4), 239-245
- https://doi.org/10.1097/00054725-199911000-00001
Abstract
Our aim was to report the clinical experience with combination treatment using tacrolimus and either azathioprine (AZA) or 6-mercaptopurine (6MP) in patients with Crohn's disease (CD) perianal fistulae. The medical records of all patients with Crohn's disease perianal fistulae seen at the Mayo Clinic from 1996-1998 who were treated with tacrolimus were reviewed. Clinical response was classified as: complete response, partial response, and nonresponse. Eleven patients were treated with oral tacrolimus for a mean duration of 22 weeks. The initial oral dose of tacrolimus ranged from 0.15 to 0.31 mg/kg/day. Azathioprine or 6MP was continued in combination with tacrolimus in seven patients and initiated simultaneously with tacrolimus in four patients. All patients improved clinically, seven had a complete response, and four had a partial response. The mean time to initial improvement was 2.4 weeks, and the mean time to complete response was 12.2 weeks. The most frequent adverse events were nausea, paresthesias, nephrotoxicity, and tremor. Patients with nephrotoxicity had a significantly higher mean initial tacrolimus dose (0.31 mg/kg/day) compared with patients who did not have nephrotoxicity (0.25 mg/kg/day) (p = 0.035); however, there was not a statistically significant association between the starting dose or mean blood level and clinical response. Combination therapy with oral tacrolimus and AZA or 6MP may be effective treatment for CD perianal fistulae. Higher initial tacrolimus doses increase the risk of nephrotoxicity without improving clinical response.Keywords
This publication has 30 references indexed in Scilit:
- Clinical Outcome Following Treatment of Refractory Inflammatory and Fistulizing Crohn's Disease With Intravenous CyclosporineThe American Journal of Gastroenterology, 1998
- H. pylori and gastric phospholipids of peptic ulcerGastroenterology, 1997
- Combined Use of Cyclosporine and Azathioprine or 6-Mercaptopurine in Pediatric Inflammatory Bowel DiseaseJournal of Pediatric Gastroenterology and Nutrition, 1996
- Highly Destructive Perianal Disease in Children with Crohnʼs DiseaseJournal of Pediatric Gastroenterology and Nutrition, 1995
- The use of cyclosporin in the management of acute exacerbations of inflammatory bowel diseaseGastroenterology, 1995
- Intracolonic administration of zileuton, a selective 5-lipoxysenase inhibitor, decreases stricture formation and accelerates healing in a rat model of chronic colitisGastroenterology, 1995
- Intravenous Cyclosporine for Steroid-Refractory Attacks of Crohnʼs DiseaseJournal of Clinical Gastroenterology, 1995
- A Comparison of Tacrolimus (FK 506) and Cyclosporine for Immunosuppression in Liver TransplantationThe New England Journal of Medicine, 1994
- Efficacy of cyclosporine in treatment of fistula of crohn's diseaseDigestive Diseases and Sciences, 1994
- Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin ANature, 1991